Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders

被引:3
|
作者
de Kemp, ECM
Moleman, P
Hoogduin, CAL
Broekman, TG
Goedhart, A
Schaap, CPDR
van den Berg, PC
机构
[1] Univ Nijmegen, Dept Clin Psychol & Personal, Nijmegen, Netherlands
[2] Moleman Res BV, Amerongen, Netherlands
[3] Bur Beta Nijmegen, Nijmegen, Netherlands
[4] Community Ment Hlth Ctr, RIAGG, Dordrecht, Netherlands
[5] Univ Groningen, Dept Clin Psychol, Groningen, Netherlands
关键词
affective disorder; depression; anxiety; primary diagnosis; pharmacotreatment;
D O I
10.1007/s00213-001-0947-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Co-morbidity of mood and anxiety disorders is often ignored in pharmacotreatment outcome studies and this complicates the interpretation of treatment response. The clinical trials are usually based on single categories from the Diagnostic and Statistical Manual of Mental Disorders (DSM). Objectives: The present study is a first attempt to differentiate the responses to anti depressants using a design that differs from that used in previous clinical trials. To avoid bias due to co-morbidity, we included patients with any DSM-III-R diagnosis of mood or anxiety disorder for which antidepressant treatment was indicated. We also explored the role of the diagnosis at the first episode in the efficacy of the different anti depressants. Methods: A total of 92 outpatients with a mood and/or anxiety disorder were randomly assigned to treatment with imipramine or fluvoxamine in a 6-week study. The diagnosis at the first episode - or primary diagnosis - was available for 78 patients, 40 with a primary depression and 38 with a primary anxiety disorder. Results: Analyses using the MIXED procedure for repeated measures showed no general differences between treatment with imipramine and treatment with fluvoxamine. When the primary diagnoses were taken into consideration, differentiation occurred. Patients with primary depression showed better responses to imipramine than to fluvoxamine. The assumption that patients with primary anxiety disorder would respond better to fluvoxamine than imipramine was observed for only the Clinical Global Impression. Conclusions: The results suggest that the nature of the first illness episode may be more valuable than the DSM categories of mood or anxiety disorders, which may lend support to the concept of primary versus secondary depression for purposes of differentiating treatment responses. Given the exploratory nature of the study, however, replication of our finding is needed.
引用
收藏
页码:67 / 73
页数:7
相关论文
共 50 条
  • [1] Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment
    Gerard, Alain
    Liard, Francois
    Crochard, Anne
    Goni, Sylvia
    Millet, Bruno
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 605 - 614
  • [2] Responses to Conflict and Cooperation in Adolescents with Anxiety and Mood Disorders
    Erin B. McClure
    Jessica M. Parrish
    Eric E. Nelson
    Joshua Easter
    John F. Thorne
    James K. Rilling
    Monique Ernst
    Daniel S. Pine
    Journal of Abnormal Child Psychology, 2007, 35 : 567 - 577
  • [3] Responses to conflict and cooperation in adolescents with anxiety and mood disorders
    McClure, Erin B.
    Parrish, Jessica M.
    Nelson, Eric E.
    Easter, Joshua
    Thorne, John F.
    Rilling, James K.
    Ernst, Monique
    Pine, Daniel S.
    JOURNAL OF ABNORMAL CHILD PSYCHOLOGY, 2007, 35 (04) : 567 - 577
  • [4] Excessive Mood Elevation and Behavioral Activation with Antidepressant Treatment of Juvenile Depressive and Anxiety Disorders: A Systematic Review
    Offidani, Emanuela
    Fava, Giovanni A.
    Tomba, Elena
    Baldessarini, Ross J.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2013, 82 (03) : 132 - 141
  • [5] Neurosteroids in the Pathophysiology and Treatment of Mood and Anxiety Disorders
    Perkins E.C.
    Newport D.J.
    Current Treatment Options in Psychiatry, 2018, 5 (4) : 377 - 400
  • [6] Treatment of perinatal mood and anxiety disorders: A review
    Misri, Shaila
    Kendrick, Kristin
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2007, 52 (08): : 489 - 498
  • [7] Dissociative symptoms in patients with mood and anxiety disorders
    Moscariello, Marianna Margherita
    Ratti, Flavia
    Quartini, Adele
    Espi Forcen, Fernando
    Nieto Munuera, Joaquin
    Bersani, Giuseppe
    RIVISTA DI PSICHIATRIA, 2010, 45 (04) : 234 - 243
  • [8] Mood and anxiety disorders in patients with multiple sclerosis
    Uguz, Faruk
    Akpinar, Zehra
    Ozkan, Ishak
    Tokgoz, Serhat
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (01) : 19 - 24
  • [9] The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders
    Dubovsky S.L.
    Dubovsky A.N.
    Current Behavioral Neuroscience Reports, 2015, 2 (3) : 154 - 164
  • [10] Mood and anxiety disorders in patients with abnormal uterine bleeding
    Kayhan, Fatih
    Alptekin, Husnu
    Kayhan, Aysegul
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2016, 199 : 192 - 197